Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[18F]fluorothymidine in preclinical tumor models

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 8, 2011, Pages 1436-1448

  Lee, Seung Jin ^a   Kang, Hye Young ^a   Kim, Seog Young ^a   Chung, Jin Hwa ^a   Oh, Seung Jun ^a   Ryu, Jin Sook ^a   Kim, Sung Bae ^a   Kang, Jong Soon ^b   Park, Song Kyu ^a,b   Kim, Hwan Mook ^a,b   Kim, Myung Hwa ^c   Moon, Dae Hyuk ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Jeil Pharmaceutical Co Ltd   (South Korea)

Author keywords

18F Fluorothymidine; Anti tubulin agent; JAC106; Positron emission tomography

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; COLCHICINE; CYCLIN A; CYCLIN B; CYCLIN E; JAC 106; THYMIDINE KINASE 1; TUBULIN; TUBULIN MODULATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL FRACTIONATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; IN VITRO STUDY; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN POLYMERIZATION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; HUMANS; MALE; MICE; MITOSIS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; THYMIDINE KINASE; TIME FACTORS; TUBULIN; TUBULIN MODULATORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052578275     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1802-4     Document Type: Article

References (36)

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65. (Pubitemid 38525281)
2. Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009;8:2086-95.
3. Ramalingam S, Belani CP. Paclitaxel for non-small cell lung cancer. Expert Opin Pharmacother 2004;5:1771-80. (Pubitemid 39117720)
4. Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, et al. MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res 2007;67:5865-71. (Pubitemid 46985021)
5. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22: 7280-95. (Pubitemid 37487160)
6. Arrieta O, González-De La Rosa CH, Aréchaga-Ocampo E, Villanueva-Rodríguez G, Cerón-Lizárraga TL, Martínez-Barrera L, et al. Randomized phase II trial of all-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3463-71.
7. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-22.
8. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-506. (Pubitemid 47572635)
9. Oguri T, Ozasa H, Uemura T, Bessho Y, Miyazaki M, Maeno K, et al. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther 2008;7:1150-5.
10. Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005;16 Suppl 4:iv14-19. (Pubitemid 43084940)
11. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Ann Oncol 2005;16:1723-39. (Pubitemid 41631235)
12. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6. (Pubitemid 28512118)
13. Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 2006;66:8558-64. (Pubitemid 44449169)
14. Lee SJ, Kim SY, Chung JH, Oh SJ, Ryu JS, Hong YS, et al. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3"-deoxy- 3"-[18F]fluorothymidine flare. Biochem Pharmacol 2010;80:1528-36.
15. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, et al. Early changes in [18F]FLT uptake after chemotherapy: An experimental study. Eur J Nucl Med Mol Imaging 2002;29:1462-9. (Pubitemid 35232048)
16. Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, et al. [18F] Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008;14:7423-9.
17. Reske SN, Deisenhofer S. Is 3"-deoxy-3"-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose? Eur J Nucl Med Mol Imaging 2006;33:38-43.
18. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-14. (Pubitemid 26301619)
19. Direcks WG, Berndsen SC, Proost N, Peters GJ, Balzarini J, Spreeuwenberg MD, et al. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: An in vitro study. Br J Cancer 2008;99:481-7.
20. Dittmann H, Jusufoska A, Dohmen BM, Smyczek-Gargya B, Fersis N, Pritzkow M, et al. 3"-Deoxy-3"-[(18)F]fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliferation after doxorubicin and docetaxel treatment. Nucl Med Biol 2009;36:163-9.
21. Monazzam A, Josephsson R, Blomqvist C, Carlsson J, Långström B, Bergström M. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer. Breast Cancer Res 2007;9:R45.
22. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3"-deoxy-3"-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 2006;12:4590-7. (Pubitemid 44297809)
23. Oyama N, Hasegawa Y, Kiyono Y, Kobayashi M, Fujibayashi Y, Ponde DE, et al. Early response assessment in prostate carcinoma by (18)F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models. Eur J Nucl Med Mol Imaging 2011;38:81-9.
24. Lee SJ, Oh SJ, Chi DY, Kil HS, Kim EN, Ryu JS, et al. Simple and highly efficient synthesis of 3"-deoxy-3"-[18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent. Eur J Nucl Med Mol Imaging 2007;34:1406-9. (Pubitemid 47312587)
25. Lee SJ, Yang EK, Kim SG. Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: Role for Zf9 dephosphorylation. Mol Pharmacol 2006;70:415-25.
26. Yang YJ, Ryu JS, Kim SY, Oh SJ, Im KC, Lee H, et al. Use of 3"- deoxy-3"-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 2006;33:412-9.
27. Sherley JL, Kelly TJ. Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells. J Biol Chem 1988;263:375-82. (Pubitemid 18041087)
28. Teicher BA, Andrews PA. Anticancer drug development guide: Preclinical screening, clinical trials, and approval. 2nd ed. Totowa: Humana; 2004. p. 138.
29. Kim SJ, Lee JS, Im KC, Kim SY, Park SA, Lee SJ, et al. Kinetic modeling of 3"-deoxy-3"-18Ffluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice. J Nucl Med 2008;49:2057-66.
30. Choi SJ, Kim SY, Kim SJ, Lee JS, Lee SJ, Park SA, et al. Reproducibility of the kinetic analysis of 3"-deoxy-3"-[(18)F] fluorothymidine positron emission tomography in mouse tumor models. Nucl Med Biol 2009;36:711-9.
31. Ke PY, Hu CM, Chang YC, Chang ZF. Hiding human thymidine kinase 1 from APC/C-mediated destruction by thymidine binding. FASEB J 2007;21:1276-84.
32. Milas L, Hunter NR, Mason KA, Kurdoglu B, Peters LJ. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 1994;54:3506-10. (Pubitemid 24225974)
33. Gan Y, Wientjes MG, Lu J, Au JL. Cytostatic and apoptotic effects of paclitaxel in human breast tumors. Cancer Chemother Pharmacol 1998;42:177-82. (Pubitemid 28329193)
34. Bading JR, Shields AF. Imaging of cell proliferation: Status and prospects. J Nucl Med 2008;49:64S-80S. (Pubitemid 351948037)
35. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S- 50S.
36. Gonzalez-Angulo AM, Hortobagyi GN. Optimal schedule of paclitaxel: Weekly is better. J Clin Oncol 2008;26:1585-7.